Literature DB >> 6829569

Nitrogen mustard therapy in children with frequent-relapsing nephrotic syndrome and steroid toxicity.

M J Schoeneman, A Spitzer, I Greifer.   

Abstract

Nitrogen mustard (HN-2) is an alkylating agent known to be effective in inducing and prolonging remissions of nephrotic syndrome in children. The fact that the drug is administered intravenously eliminates the problem of compliance, and the fact that the treatment needs to be given only for a few days may lower the incidence of side-effects observed with other cytotoxic agents. We administered HN-2 to 12 children with the steroid-sensitive frequent-relapsing form of nephrotic syndrome, who had evidence of steroid toxicity. Life table analysis reveals a 46% sustained remission rate after 27 mo of follow-up. Complications of HN-2 treatment included only mild thrombophlebitis (2 patients) and mild local paresthesia (1 patient).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6829569     DOI: 10.1016/s0272-6386(83)80094-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Minimal change nephrotic syndrome and cyclophosphamide.

Authors:  R S Trompeter
Journal:  Arch Dis Child       Date:  1986-08       Impact factor: 3.791

2.  Nitrogen mustard therapy and nephrotic syndrome.

Authors:  R Arumugam; A R Watson
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 3.  The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.

Authors:  J Brodehl
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 4.  Management of nephrotic syndrome in childhood.

Authors:  T Melvin; W Bennett
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 5.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

Review 6.  History of Nephrotic Syndrome and Evolution of its Treatment.

Authors:  Abhijeet Pal; Frederick Kaskel
Journal:  Front Pediatr       Date:  2016-05-30       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.